Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

被引：172

作者：

Bodei, L

Cremonesi, M

Grana, C

Rocca, P

Bartolomei, M

Chinol, M

Paganelli, G

机构：

[1] European Inst Oncol, Div Nucl Med, I-20141 Milan, Italy

[2] European Inst Oncol, Med Phys Div, I-20141 Milan, Italy

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2004年 / 31卷 / 07期

关键词：

Y-90-DOTATOC; neuroendocrine tumours; receptor radionuclide therapy; somatostatin receptors;

D O I：

10.1007/s00259-004-1571-4

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue Y-90-[DOTA](0)-Tyr(3)-octreotide [Y-90-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.

引用

收藏

页码：1038 / 1046

页数：9

相关论文

共 43 条

[1]

Behr TM, 2002, EUR J NUCL MED MOL I, V29, P277, DOI 10.1007/s00259-001-0713-1

[2] Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:: a phase I study [J].

Bodei, L ;

Cremonesi, M ;

Zoboli, S ;

Grana, C ;

Bartolomei, M ;

Rocca, P ;

Caracciolo, M ;

Mäcke, HR ;

Chinol, M ;

Paganelli, G .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (02) :207-216

[3] Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl [J].

Bodei, L ;

Chinol, M ;

Cremonesi, M ;

Paganelli, G .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (08) :1099-1100

[4] Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney [J].

Boerman, OC ;

Oyen, WJG ;

Corstens, FHM .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (10) :1447-1449

[5] Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up [J].

Bontenbal, M ;

Foekens, JA ;

Lamberts, SWJ ;

de Jong, FH ;

van Putten, WLJ ;

Braun, HJ ;

Burghouts, JTM ;

van der Linden, GHM ;

Klijn, JGM .

BRITISH JOURNAL OF CANCER, 1998, 77 (01) :115-122

[6] HYPOTHALAMIC POLYPEPTIDE THAT INHIBITS SECRETION OF IMMUNOREACTIVE PITUITARY GROWTH-HORMONE [J].

BRAZEAU, P ;

VALE, W ;

BURGUS, R ;

LING, N ;

BUTCHER, M ;

RIVIER, J ;

GUILLEMIN, R .

SCIENCE, 1973, 179 (4068) :77-79

[7] Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide:: The experience of the European Institute of Oncology Group [J].

Chinol, M ;

Bodei, L ;

Cremonesi, M ;

Paganelli, G .

SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (02) :141-147

[8] Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity [J].

Chinol, M ;

Casalini, P ;

Maggiolo, M ;

Canevari, S ;

Omodeo, ES ;

Caliceti, P ;

Veronese, FM ;

Cremonesi, M ;

Chiolerio, F ;

Nardone, E ;

Siccardi, AG ;

Paganelli, G .

BRITISH JOURNAL OF CANCER, 1998, 78 (02) :189-197

[9] Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide:: implications for internal radiotherapy with 90Y-DOTATOC [J].

Cremonesi, M ;

Ferrari, M ;

Zoboli, S ;

Chinol, M ;

Stabin, MG ;

Orsi, F ;

Maecke, HR ;

Jermann, E ;

Robertson, C ;

Fiorenza, M ;

Tosi, G ;

Paganelli, G .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (08) :877-886

[10]

Cremonesi M, 2002, CANCER BIOTHER RADI, V17, P344

← 1 2 3 4 5 →